Females With Severe or Moderate Hemophilia A or B: A Multi-Center Study
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To collect and analyze data on females with hemophilia so as to better define the difference between the study population and the male population with hemophilia.
| Condition |
|---|
|
Hemophilia A Hemophilia B |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Retrospective |
| Official Title: | Females With Severe or Moderate Hemophilia A or B: A Multi-Center Study |
- The prevalence of females with severe or moderate hemophilia A or B in the United States. [ Time Frame: Study Duration ] [ Designated as safety issue: No ]
- Collect existing data on the genetic and/or chromosomal causes for severe and moderate hemophilia A and B in females in the United States. [ Time Frame: Study Duration ] [ Designated as safety issue: No ]
- To determine the natural history of hemophilia in females by collecting and analyzing data on the symptoms, treatment patterns, and complications of hemophilia in this cohort. [ Time Frame: Study Duration ] [ Designated as safety issue: No ]
- Collect and analyze data on the health-related quality of life and psychosocial adaptation to disease of females in the United States. [ Time Frame: Study Duration ] [ Designated as safety issue: No ]
| Enrollment: | 22 |
| Study Start Date: | April 2005 |
| Study Completion Date: | January 2010 |
| Primary Completion Date: | January 2010 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
Females with Hemophilia
Females with severe or moderate Hemophilia A or B.
|
Detailed Description:
This study is designed as an epidemiological study with retrospective clinical and genetic data collection and prospective quality of life (QOL) data collections and genotyping of subjects without current molecular diagnosis. Data on the genetic/chromosomal etiology of the condition will be collected through chart review. For those subjects who have not had molecular or cytogenetic analysis, molecular and cytogenetic testing will be offered after genetic counseling. Those subjects who agree to have genetic testing will have 5-10 ml of blood drawn and sent to the cytogenetic laboratory at Weill Cornell Medical College for testing to determine the chromosomal complement, and 5 ml of blood sent to Dr. Arupa Ganguly at the University of Pennsylvania for the identification of a factor VIII or factor IX mutation, and X-chromosome inactivation studies.
Eligibility| Ages Eligible for Study: | 1 Month and older |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Females with severe or moderate (less than 5%) hemophilia A or B.
Inclusion Criteria:
- Females with severe (FVIII<0.01u/dl) or moderate (FVIII-0.01<0.06 u/dl) hemophilia A
- Females with severe (FIX<0.01u/dl) or moderate (FIX-0.01<0.06u/dl) hemophilia B
- Willingness to participate in the study.
Exclusion Criteria:
- Subjects who do not meet the inclusion criteria with respect to gender or hemophilia severity.
Contacts and Locations| United States, California | |
| City of Hope National Medical Center | |
| Duarte, California, United States, 91010 | |
| United States, Colorado | |
| Mountain States Regional Hemophilia and Thrombosis Center | |
| Aurora, Colorado, United States, 80045 | |
| United States, District of Columbia | |
| Georgetown University Hospital | |
| Washington, District of Columbia, United States, 20007 | |
| United States, Georgia | |
| Emory University Hemophilia Program Office | |
| Atlanta, Georgia, United States, 30322 | |
| United States, Illinois | |
| Northwestern University | |
| Chicago, Illinois, United States, 60611 | |
| United States, Kentucky | |
| University of Kentucky Hemophilia Treatment Center | |
| Lexington, Kentucky, United States, 40536 | |
| United States, Massachusetts | |
| Boston Hemophilia Center- Children's Hospital | |
| Boston, Massachusetts, United States, 02115 | |
| United States, Michigan | |
| Henry Ford Hospital Adult Hemophilia and Thrombosis Treatment Center | |
| Detroit, Michigan, United States, 48202 | |
| United States, New Jersey | |
| Newark Beth Israel Medical Center | |
| Newark, New Jersey, United States, 07112 | |
| United States, New York | |
| Hemophilia Center of Western New York - Pediatric | |
| Buffalo, New York, United States, 14222 | |
| Long Island Jewish Medical Center | |
| New Hyde Park, New York, United States, 11040 | |
| Weill Cornell Medical College | |
| New York, New York, United States, 10065 | |
| Mary M. Gooley Hemophilia Center, Inc. | |
| Rochester, New York, United States, 14621 | |
| United States, Ohio | |
| Children's Hospital Medical Center of Akron | |
| Akron, Ohio, United States, 44308 | |
| Cincinnati Children's Hospital Medical Center | |
| Cincinnati, Ohio, United States, 45229 | |
| United States, Oklahoma | |
| Oklahoma Center for Bleeding Disorders | |
| Oklahoma City, Oklahoma, United States, 73104 | |
| United States, Pennsylvania | |
| Children's Hospital of Philadelphia | |
| Philadelphia, Pennsylvania, United States, 19104 | |
| United States, Texas | |
| Gulf States Hemophilia and Thrombophilia Center | |
| Houston, Texas, United States, 77030 | |
| Puerto Rico | |
| Puerto Rico Hemophilia Treatment Center | |
| San Juan, Puerto Rico, 00936 | |
| Principal Investigator: | William B Mitchell, MD | Weill Medical College of Cornell University |
More Information
No publications provided
| Responsible Party: | Weill Medical College of Cornell University |
| ClinicalTrials.gov Identifier: | NCT00936845 History of Changes |
| Other Study ID Numbers: | Females with Hemophilia |
| Study First Received: | July 9, 2009 |
| Last Updated: | December 6, 2012 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Hemophilia B Hemophilia A Blood Coagulation Disorders, Inherited Blood Coagulation Disorders Hematologic Diseases Coagulation Protein Disorders Hemorrhagic Disorders |
Genetic Diseases, Inborn Genetic Diseases, X-Linked Factor VIII Coagulants Hematologic Agents Therapeutic Uses Pharmacologic Actions |
ClinicalTrials.gov processed this record on June 17, 2013